Press Release
Thursday, November 24, 2011

APPROVAL MOMENTUM FOR ONCOLOGY PRODUCTS CONTINUES WITH TWO MORE USFDA APPROVALS

Approval for additional strength of Carboplatin
Tentative approval for additional strength of Oxaliplatin

November 24, 2011, Bangalore: Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited (Strides) today announced that it has received approvals from USFDA for:

- **Carboplatin Injection 10 mg/mL (Aqueous solution), packaged in 1000 mg/100 mL, Pharmacy Bulk Packages.**

- **Oxaliplatin for Injection USP (Lyophilized) packaged in 50 mg and 100 mg single-use vials (Tentative approval)**

The Company had earlier received approval for Carboplatin Injection 10 mg/mL packaged in 50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL and 600 mg/60 mL Multi-dose vials. According to IMS data, the US market for generic Carboplatin is approximately USD 35 Million. Carboplatin is part of the Oncology portfolio licensed to Pfizer in January 2010 for the US market and expected to be launched shortly.

The Company also received tentative approval for additional strength of Oxaliplatin Injection. According to IMS data, the US market for Oxaliplatin is approximately USD 1.4 Billion. The Company had earlier received tentative approval for Oxaliplatin Injection, 5 mg/mL, packaged in 50 mg/10 mL, 100 mg/20 mL, and 200 mg/40 mL single dose vials. While other generic Companies approved for this product are expected to launch the product in August 2012, Strides will issue further updates on this product in April 2012.
About Carboplatin

Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents, and in secondary treatment of advanced ovarian carcinoma which has recurred after prior chemotherapy.

About Oxaliplatin

Oxaliplatin is a chemotherapy drug used to treat advanced cancer of the colon and rectum. It is used in combination with other medications to slow or stop cancer cell growth.

About Agila Specialties

Agila Specialties Private Limited is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company’s restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 8 world class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila’s marketing network covers 70 countries and it has partnerships with some of the world’s leading pharmaceutical companies for both developed and emerging markets.

About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company’s website at www.stridesarco.com. For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>PR Consultancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. V.S. Iyer, CEO - Agila +91 80 6784 0111</td>
<td>Corporate Voice</td>
</tr>
<tr>
<td>Mr. Ajay Singh : +91 80 6784 0813 Mr. Kannan N : +91 98450 54745 (Investors)</td>
<td>Mahesh Nair, +91 9880376648; <a href="mailto:maheshn@corvoshandwick.co.in">maheshn@corvoshandwick.co.in</a></td>
</tr>
<tr>
<td>Hiba Kunil +91 98807 26372; <a href="mailto:hiba@corvoshandwick.co.in">hiba@corvoshandwick.co.in</a></td>
<td></td>
</tr>
</tbody>
</table>